Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Yang, Zhi Tao ^a   Wu, Lin ^a   Liu, Xiao Ying ^a   Zhou, Min ^a   Li, Jie ^a   Wu, Jia Yin ^a   Cai, Yong ^a   Mao, En Qiang ^a   Chen, Er Zhen ^a   Lortholary, Olivier ^b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

Appropriate antifungal therapy; Bloodstream infection; Candida spp; Survival

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA BLOODSTREAM INFECTION; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA SAKE; CANDIDA TROPICALIS; CANDIDEMIA; CHINA; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; OUTCOME ASSESSMENT; PICHIA GUILLIERMONDII; RETROSPECTIVE STUDY; SPECIES DISTRIBUTION; UNIVERSITY HOSPITAL; AGED; CANDIDA; CANDIDIASIS; COMORBIDITY; COMPLICATION; CROSS INFECTION; EPIDEMIOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; TEACHING HOSPITAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; CHINA; COMORBIDITY; CROSS INFECTION; FEMALE; HOSPITALS, TEACHING; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84901497295     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-241     Document Type: Article

References (50)

1. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Tauber MG, Pittet D. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004, 38(3):311-320. 10.1086/380637, 14727199.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317. 10.1086/421946, 15306996.
3. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 2011, 6(9):e24198. 10.1371/journal.pone.0024198, 3174155, 21935385.
4. Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000-2009. Jpn J Infect Dis 2012, 65(6):510-515. 10.7883/yoken.65.510, 23183203.
5. Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, Chu CC, Hsueh PR, Chang SC, Chen YC. Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. J Microbiol Immunol Infect 2014, 47(2):95-103. 10.1016/j.jmii.2012.08.025, 23063082.
6. Bitar D, Lortholary O, Dromer F, Coignard B, Che D. Mycoses invasives en France métropolitaine, PMSI, incidence, létalité et tendances 2001-2010 incidence, létalité et tendances. Bulletin épidémiologique hebdomadaire 2013, BEH12-13/16 Avril 2013?:109-114.
7. Maganti H, Yamamura D, Xu J. Prevalent nosocomial clusters among causative agents for candidemia in Hamilton. Canada. Med Mycol 2011, 49(5):530-538.
8. Wu JQ, Zhu LP, Ou XT, Xu B, Hu XP, Wang X, Weng XH. Epidemiology and risk factors for non-Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital. Med Mycol 2011, 49(5):552-555.
9. Méchaï F, Bruneel F, Lanternier F, Legriel S, Bédos J-P, Lortholary O. Chapter 7: Pathogens in Sepsis: Fungi, Parasites. Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care 2009, Wiley Online Library. published online, Cavaillon J-M, Adrie C, DOI:?10.1002/9783527626151.ch7.
10. Chang A, Neofytos D, Horn D. Candidemia in the 21st century. Future Microbiol 2008, 3(4):463-472. 10.2217/17460913.3.4.463, 18651817.
11. Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, Iatta R, Giglio M, Dalfino L, Bruno F, Puntillo F. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 2013, 41(3):645-653. (PMID: 23463186), 10.1007/s15010-013-0432-0, 3671106, 23463186.
12. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance (R) registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 2012, 73(4):293-300. 10.1016/j.diagmicrobio.2012.06.012, 22789847.
13. Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, Einsele H, Heinz WJ. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol 2012, 50(1):50-55. 10.3109/13693786.2011.587211, 21696259.
14. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz PDPM, Hernandez-Caballero C, Aznar-Martin J, Cisneros JM, Ortiz-Leyba C. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010, 54(8):3149-3154. 10.1128/AAC.00479-10, 2916332, 20498325.
15. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011, 55(2):532-538. 10.1128/AAC.01128-10, 3028765, 21078946.
16. Pappas PG, Kauffman CA, Andes D, Benjamin DJ, Calandra TF, Edwards JJ, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD., Infectious Diseases Society of America Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535. 10.1086/596757, 19191635, Infectious Diseases Society of America.
17. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ., ESCMID Fungal Infection Study Group ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012, 18(Suppl 7):19-37. ESCMID Fungal Infection Study Group.
18. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance (R)) registry, 2004-2008. Diagn Microbiol Infect Dis 2012, 74(4):323-331. 10.1016/j.diagmicrobio.2012.10.003, 23102556.
19. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006, 25(7):419-425. 10.1007/s10096-006-0159-2, 16773391.
20. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007, 60(3):613-618. 10.1093/jac/dkm212, 17576697.
21. Kludze-Forson M, Eschenauer GA, Kubin CJ, Della-Latta P, Lam SW. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol 2010, 48(2):436-439. 10.3109/13693780903208256, 20141378.
22. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz PDPM, Hernandez-Caballero C, Lepe-Jimenez JA. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother 2013, 68(1):206-213. 10.1093/jac/dks347, 22945914.
23. Arnold HM, Micek ST, Shorr AF, Zilberberg MD, Labelle AJ, Kothari S, Kollef MH. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010, 30(4):361-368. 10.1592/phco.30.4.361, 20334456.
24. Ha YE, Peck KR, Joo EJ, Kim SW, Jung SI, Chang HH, Park KH, Han SH. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother 2012, 56(7):3950-3956. 10.1128/AAC.06258-11, 3393400, 22526315.
25. Li F, Wu L, Cao B, Zhang Y, Li X, Liu Y. Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. Bmc Infect Dis 2013, 13(1):353. 10.1186/1471-2334-13-353, 3733982, 23899244.
26. Zhang L, Wang H, Mao L, Zhao H, Xiao M, Xu Y. Evaluation of ATB® Fungus 3 for Antifungal Susceptibility Testing of Candida spp. by visual and automatic readings against Broth Microdilution Method. ECCMID 2013, in Berlin, 27-30 April 2013:P1600.
27. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012, 50(9):2846-2856. 10.1128/JCM.00937-12, 3421803, 22740712.
28. Li D, Zhang W, Zheng S, Ma Z, Zhang P, Liu Z. Surveillance study of candidemia in cancer patients in North China. Med Mycol 2013, 51(4):378-384. 10.3109/13693786.2012.727481, 23046201.
29. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002, 45(5-6):141-145.
30. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, Magill SS, Derado G, Park BJ, Chiller TM. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012, 55(10):1352-1361. 10.1093/cid/cis697, 22893576.
31. Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis 2011, 15(11):e759-e763. 10.1016/j.ijid.2011.06.006, 21840742.
32. Gomez J, Garcia-Vazquez E, Espinosa C, Ruiz J, Canteras M, Hernandez-Torres A, Banos V, Herrero JA, Valdes M. Nosocomial candidemia at a general hospital: the change of epidemiological and clinical characteristics. A comparative study of 2 cohorts (1993-1998 versus 2002-2005). Rev Iberoam Micol 2009, 26(3):184-188. 10.1016/j.riam.2009.02.003, 19635438.
33. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, Guzman-Blanco M, Santolaya ME, Thompson L, Sifuentes-Osornio J, Echevarria JI, Colombo AL., Latin American Invasive Mycosis Network Epidemiology of candidemia in latin america: a laboratory-based survey. PLoS One 2013, 8(3):e59373. 10.1371/journal.pone.0059373, 3601956, 23527176, Latin American Invasive Mycosis Network.
34. Poikonen E, Lyytikainen O, Anttila VJ, Kuusela P, Koukila-Kahkola P, Ollgren J, Ruutu P. Nosocomial candidaemia in a Finnish tertiary care centre during 1987-2004. Scand J Infect Dis 2009, 41(8):590-596. 10.1080/00365540903022824, 19488931.
35. Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Leitz C, Lemming LE, Nielsen L, Olesen B, Rosenvinge FS, Røder BL, Schønheyder HC. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013, 19(8):E343-53. 10.1111/1469-0691.12212, 23607326.
36. Richet H, Roux P, Des Champs C, Esnault Y, Andremont A. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002, 8(7):405-412. 10.1046/j.1469-0691.2002.00446.x, 12199850.
37. Munoz P, Giannella M, Fanciulli C, Guinea J, Valerio M, Rojas L, Rodriguez-Creixems M, Bouza E. Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital. Clin Microbiol Infect 2011, 17(10):1538-1545. 10.1111/j.1469-0691.2010.03338.x, 20718804.
38. Guimaraes T, Nucci M, Mendonca JS, Martinez R, Brito LR, Silva N, Moretti ML, Salomao R, Colombo AL. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Int J Infect Dis 2012, 16(6):e442-e447. 10.1016/j.ijid.2012.02.005, 22486857.
39. Ben-Ami R, Rahav G, Elinav H, Kassis I, Shalit I, Gottesman T, Megged O, Weinberger M, Ciobotaro P, Shitrit P, Weber G, Paz A, Miron D, Oren I, Bishara J, Block C, Keller N, Kontoyiannis DP, Giladi M., Israeli Candidaemia Study Group Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel. Clin Microbiol Infect 2013, 19(8):752-6. 10.1111/1469-0691.12004, 23005038, Israeli Candidaemia Study Group.
40. Chen TC, Chen YH, Chen YC, Lu PL. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents. Kaohsiung J Med Sci 2012, 28(6):306-315. 10.1016/j.kjms.2011.11.011, 22632885.
41. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R., ECMM Working Group on Candidaemia Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23(4):317-322. 10.1007/s10096-004-1103-y, 15029512, ECMM Working Group on Candidaemia.
42. Parmeland L, Gazon M, Guerin C, Argaud L, Lehot JJ, Bastien O, Allaouchiche B, Michallet M, Picot S, Bienvenu AL. Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade. Med Mycol 2013, 51(1):33-37. 10.3109/13693786.2012.686673, 22680978.
43. Lai CC, Chu CC, Wang CY, Tsai HY, Cheng A, Lee YC, Huang YT, Liao CH, Hsueh PR. Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int J Antimicrob Agents 2012, 40(4):349-353. 10.1016/j.ijantimicag.2012.05.024, 22819796.
44. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48(4):1366-1377. 10.1128/JCM.02117-09, 2849609, 20164282.
45. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011, 38(1):65-69. 10.1016/j.ijantimicag.2011.02.016, 21514797.
46. Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Moller J, Nielsen L, Rosenvinge FS, Røder B, Schønheyder HC, Thomsen MK, Truberg K. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011, 49(1):325-334. 10.1128/JCM.01811-10, 3020479, 20980569.
47. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O., AmarCand Study Group Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37(5):1612-1618. 10.1097/CCM.0b013e31819efac0, 19325476, AmarCand Study Group.
48. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M., ESCMID Fungal Infection Study Group ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012, 18(Suppl 7):53-67. ESCMID Fungal Infection Study Group.
49. Bassetti M, Molinari MP, Mussap M, Viscoli C, Righi E. Candidaemia in internal medicine departments: the burden of a rising problem. Clin Microbiol Infect 2013, 19(6):E281-E284. 10.1111/1469-0691.12155, 23414070.
50. Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010, 65(8):1765-1770. 10.1093/jac/dkq216, 20554567.